Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
Profusa, Inc., a Nasdaq-listed digital health company specializing in biosensing technologies, announced an Option Agreement to acquire G3 Vision Labs, a commercial-stage diagnostics company with an estimated $111 million in 2025 net revenues. The acquisition would establish Profusa as a national public diagnostics company with CLIA-certified labs …